Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Dec 06, 2018 9:00 AM - Dec 07, 2018 5:00 PM

2018 DIA China MASTER CLASS ON BIOSIMILARS: Executive Perspectives on Development, Regulatory and Commercial Aspects

Faculty

Hoss A Dowlat, PhD

Hoss A Dowlat, PhD

Vice President, Regulatory Affairs EU-USA, Global Strategy, PharmaBio Consulting (Life Sciences), Germany

EU/US/Japan Regulatory submissions, Scientific Advice, NDA/BLA//MAA or IND/CTA. Biologics, Orphan Drugs. Biosimilars. Pharm dev, clinical research and medicinal safety including EU PIPs and RMPs, and US/EU PI.

Weining  HU

Weining HU

VP of Global Regulatory Affairs, Gan & Lee Pharmaceuticals, China

Joe  Zhang

Joe Zhang

Co-founder and CEO, BJ Bioscience Inc., China

Carol  Zhu, MBA

Carol Zhu, MBA

Vice President, Portfolio and Project Management, JW Therapeutics, China

Carol Zhu, RPh, MBA, serves as Senior Vice President and Managing Director for DIA Greater China. She joined DIA from the Bill & Melinda Gates Foundation, where she was the Senior Program Officer for R&D Programs. Prior to her work at the Gates Foundation, she was Founder and Chief Executive Officer of START Shanghai, one of the first phase 1 oncology service companies in China. She also held positions at Merck Sharp & Dohme and GlaxoSmithKline, where she was key to establishing GSK’s R&D Center in Shanghai. Ms. Zhu earned her Masters Degree in Business Administration from Rutgers University and her undergraduate degree in pharmaceutical science from Peking University Health Science Center (Beijing Medical University).

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.